

Research Letter | Public Health

Vaccination Intentions During Pregnancy and Among Parents of Young Children

Lavanya Vasudevan, PhD, MPH, CPH; Rachael M. Porter, MPH; Walter A. Orenstein, MD, DSc; Tara M. Vogt, PhD, MPH; Robert A. Bednarczyk, PhD

Introduction

Many parents in the US choose to delay or refuse vaccines that are recommended for their child from birth to age 18 months.¹⁻⁴ Research is necessary to understand the value of intervening during pregnancy to proactively support parents with vaccination decisions before the birth of the child, as implementation of such interventions will require substantial engagement of health care

Supplemental content

Author affiliations and article information are listed at the end of this article.

Table. Characteristics From 2 Concurrent National Surveys Conducted Among Participants Who Were Pregnant and Parents of Young Children Aged O to 5 Years

	Participants, unweighted No. (weighted %) ^{a,b}		
Characteristics	Pregnant (n = 174)	Parent of young children (n = 1765)	
Trimester of pregnancy ^c			
First	60 (30.7)	NA	
Second	60 (37.5)	NA	
Third	53 (31.4)	NA	
Pregnancy parity			
Nulliparous	68 (37.6)	NA	
Parous	106 (62.4)	NA	
Age of youngest child, y ^d			
0-2	NA	904 (54.2)	
3-5	NA	847 (45.3)	
Age, y			
18-29	46 (36.0)	277 (21.9)	
≥30 ^e	128 (64.0)	1488 (78.1)	
Education level			
Less than high school	8 (9.2)	71 (6.4)	
High school	26 (20.1)	220 (24.2)	
Some college	37 (21.3)	433 (24.2)	Abbreviation: NA, not applicable.
Bachelor's degree or higher	103 (49.4)	1041 (45.1)	^a Unweighted values represent actual numbers
Race and ethnicity ^f			reported in dataset.
Black or African American, non-Hispanic	17 (14.4)	154 (11.4)	 ^b Weighted percentages calculated using geodemographic weights obtained from the panel provider.⁵
Hispanic	34 (27.0)	300 (21.7)	
White, non-Hispanic	112 (52.9)	1174 (56.0)	•
≥2 races and other, non-Hispanic	11 (5.7)	137 (10.9)	^c Trimester of pregnancy unknown for one participant reporting pregnancy.
Household income, \$			
<75 000	79 (39.0)	746 (36.1)	^d Age of youngest child unknown for 14 participants who said they were parents.
≥75 000	95 (61.0)	1019 (63.9)	^e Age categories for participants aged 30-44 years and
Marital status ⁹			45 years and older were combined due to small
Currently married	117 (69.0)	1316 (75.6)	cell size.
Not currently married	52 (27.6)	449 (24.4)	^f Categories "Other, non-Hispanic" and " \geq 2 races,
Current employment status			non-Hispanic" combined due to small cell size. Races
Working full-time	94 (54.0)	1040 (66.5)	included in "Other, non-Hispanic" include: American
Working part-time	29 (16.1)	289 (12.2)	Indian or Alaska Native, Asian, Native Hawaiian or
Not working	51 (29.9)	436 (21.4)	other Pacific Islander, and different race. Race and
Residence			ethnicity data were provided by the panel provider
Urban	138 (77.6)	1380 (79.5)	and not directly collected as part of the survey.
Rural and suburban	30 (22.4)	331 (20.5)	^g Category for not currently married included widowed, divorced, separated, and never married.

Open Access. This is an open access article distributed under the terms of the CC-BY License.

JAMA Network Open. 2025;8(7):e2520667. doi:10.1001/jamanetworkopen.2025.20667

JAMA Network Open | Public Health

professionals and entities outside of the pediatric care setting. Therefore, 2 concurrent national cross-sectional surveys were conducted in April 2024 to describe vaccination intentions during pregnancy and vaccination behaviors after the child's birth for all vaccines recommended for children from birth to age 18 months.¹

Methods

This survey study followed Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) reporting guidelines. Participants were recruited from a nationally representative panel of US adults with a sampling frame covering nearly 100% of US households.⁵ Eligibility was limited to English language survey takers and those aged 18 years and older who self-reported pregnancy and parent status. Eligible panel members received the survey link from the panel provider. Those opting in after reading the implied consent script self-administered the survey using an online survey platform. Authors retained full ownership of the data. Participants who were pregnant were asked about vaccination intention for their child after birth with the question: "Will your child receive any vaccinations after birth?" (with response options of "yes," "no," and "I don't know"). Those responding yes were asked, "Do you plan to refuse or choose not to get 1 or more recommended vaccines (including seasonal flu or COVID-19 vaccines) for your child after birth?" followed by, "Do you plan to delay or space out ANY recommended vaccines (including seasonal flu or COVID-19 vaccines) for your child after birth?" (responses for both questions were "yes," "no," or "I don't know"). Parents were asked the same questions rephrased to assess actual vaccination for their youngest child. Descriptive analyses were conducted in SAS version 9.4 (SAS Institute), with applied geodemographically calibrated sample weights. A 6-level outcome variable was created to describe vaccination decisions: (1) accept all vaccines, (2) delay some or all vaccines, (3) delay some and refuse some vaccines, (4) refuse some vaccines, (5) refuse all vaccines, and (6) undecided



Figure. Childhood Vaccination Intention by Parity and Childhood Vaccination Behaviors Reported by Parents

JAMA Network Open. 2025;8(7):e2520667. doi:10.1001/jamanetworkopen.2025.20667

JAMA Network Open | Public Health

(eTables 1 and 2 in Supplement 1). The study protocol was approved by the Emory University institutional review board.

Results

A total of 174 pregnant participants (182 surveyed [95.6% completion rate]; 128 aged 30 years or older [64.0%]; 34 Hispanic [27.0%], 17 non-Hispanic Black [14.4%], 112 non-Hispanic White [52.9%]) and 1765 parents (1874 surveyed [94.2% completion rate]; 1488 aged 30 years or older [78.1%]; 300 Hispanic [21.7%], 154 non-Hispanic Black [11.4%], 1174 non-Hispanic White [56.0%]) completed the survey. Among pregnant participants, 68 pregnancies (37.6%) were nulliparous (**Table**). Approximately half of participants had a bachelor's degree or higher (103 pregnant participants [49.4%]; 1041 parents [45.1%]); more participants were currently married vs not (117 pregnant participants [69.0%]; 1316 parents [75.6%]) and resided in an urban vs rural or suburban areas (138 pregnant participants [77.6%]; 1380 parents [79.5%]).

The proportions intending to accept or accepting all recommended vaccines for children were similar among pregnant participants and parents (**Figure**). The proportion intending to refuse or refusing some or all vaccines for their child (without delays) was lowest among nulliparous pregnant participants (5 of 68 [4%]) and highest among parents (391 of 1765 [33%]). Uncertainty about childhood vaccination was highest among nulliparous pregnant participants (31 of 68 [48%]) and lowest among parents of young children (78 of 1765 [4%]).

Discussion

Given the high decisional uncertainty during pregnancy about vaccinating children after birth, there may be value in intervening during pregnancy to proactively support families with childhood vaccination decisions. Strengths of our study include the national scope of the surveys. Study limitations include the inability to confirm concordance between vaccine intentions during pregnancy and future childhood vaccination behaviors, the potential influence of prior vaccination decisions for older children, the small counts in some response options that may create unstable estimates, and differences in demographic characteristics between samples. Future interventions should account for differences in uptake of seasonal (ie, COVID-19, influenza) vs routinely recommended vaccines. Future studies with longitudinal follow-up may shed further light on evolution of vaccination decisions from pregnancy to parenthood, and the effectiveness of intervening proactively during pregnancy.

ARTICLE INFORMATION

Accepted for Publication: May 9, 2025.

Published: July 15, 2025. doi:10.1001/jamanetworkopen.2025.20667

Open Access: This is an open access article distributed under the terms of the CC-BY License. © 2025 Vasudevan L et al. *JAMA Network Open*.

Corresponding Author: Lavanya Vasudevan, PhD, MPH, CPH, Hubert Department of Global Health, Rollins School of Public Health, Emory University, 1518 Clifton Rd NE, Atlanta, GA 30322 (lavanya.vasudevan@emory.edu).

Author Affiliations: Hubert Department of Global Health, Rollins School of Public Health, Emory University, Atlanta, Georgia (Vasudevan, Porter, Orenstein, Bednarczyk); Department of Medicine, School of Medicine, Emory University, Atlanta, Georgia (Orenstein); National Center for Immunization and Respiratory Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia (Vogt).

Author Contributions: Dr Vasudevan and Ms Porter had full access to all of the data in the study and take responsibility for the integrity of the data and the accuracy of the data analysis. Dr Vasudevan and Ms Porter contributed equally to this work.

JAMA Network Open. 2025;8(7):e2520667. doi:10.1001/jamanetworkopen.2025.20667

JAMA Network Open | Public Health

Concept and design: Vasudevan, Porter, Vogt.

Acquisition, analysis, or interpretation of data: Vasudevan, Porter, Orenstein, Bednarczyk.

Drafting of the manuscript: Vasudevan, Porter, Bednarczyk.

Critical review of the manuscript for important intellectual content: All authors.

Statistical analysis: Porter, Bednarczyk.

Obtained funding: Vasudevan.

Administrative, technical, or material support: Vasudevan, Orenstein, Vogt.

Supervision: Vasudevan.

Conflict of Interest Disclosures: Dr Orenstein reported receiving consulting fees from Sanofi, Merck, and Moderna during the conduct of the study. No other disclosures were reported.

Funding/Support: The research presented in this publication was supported by a cooperative agreement (No. U01IP001200) with the Centers for Disease Control and Prevention (CDC).

Role of the Funder/Sponsor: The CDC provided input on the design and conduct of the study, interpretation of data, manuscript preparation, review, and approved the decision to submit the manuscript for publication, but was not directly involved in data collection, management, and analysis.

Disclaimer: The content is solely the responsibility of the authors and does not necessarily represent the official views of the CDC.

Data Sharing Statement: See Supplement 2.

Additional Contributions: The authors thank all survey respondents for their participation in the survey. The authors acknowledge support from Ilse Campos, MPH (Emory University), Abby Cohen, BA (Ipsos), and Sergei Rodkin, PhD (Ipsos), for survey implementation. Contributors received no additional compensation.

REFERENCES

1. Centers for Disease Control and Prevention. Child and adolescent immunization schedule by age, recommendations for ages 18 years or younger, United States, 2024. Updated June 27, 2024. Accessed August 26, 2024. https://www.cdc.gov/vaccines/hcp/imz-schedules/child-adolescent-age.html

2. Jones JM, Fleming-Dutra KE, Prill MM, et al. Use of nirsevimab for the prevention of respiratory syncytial virus disease among infants and young children: recommendations of the advisory committee on immunization practices–United States, 2023. *MMWR Morb Mortal Wkly Rep.* 2023;72(34):920-925. doi:10.15585/mmwr. mm7234a4

3. Olusanya OA, Masters NB, Zhang F, et al. Sociodemographic trends and correlation between parental hesitancy towards pediatric COVID-19 vaccines and routine childhood immunizations in the United States: 2021-2022 National Immunization Survey-Child COVID module. *Vaccines (Basel)*. 2024;12(5):495. doi:10.3390/vaccines12050495

4. Nguyen KH, Chen S, Zhao R, Vasudevan L, Beninger P, Bednarczyk RA. Vaccination patterns and up-to-date status of children 19-35 months, 2011-2021. *Vaccine*. 2024;42(7):1617-1629. doi:10.1016/j.vaccine.2024.01.096

5. Ipsos. KnowledgePanel sampling and weighting methodology. 2024. Accessed May 9, 2025. https://www.ipsos. com/sites/default/files/kpsamplingandweighting.pdf

SUPPLEMENT 1.

eTable 1. Vaccine Decision Outcome Variable Categorization, by Vaccine Intention Questions Asked in a Survey of Participants Who Are Pregnant

eTable 2. Vaccine Decision Outcome Variable Categorization, by Vaccine Behavior Questions Asked in Survey of Parents of Young Children (0-5 Years)

SUPPLEMENT 2.

Data Sharing Statement